NCT01718327View on ClinicalTrials.gov

A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 1, 2011

Primary Completion Date

November 17, 2016

Study Completion Date

November 17, 2016

Conditions
Unresectable and Advanced Cholangiocarcinoma
Interventions
DRUG

Sunitinib

sunitinib dose :37.5mg/day

Trial Locations (6)

13005

CHU La Timone, Marseille

69008

Hôpital privé Jean Mermoz, Lyon

75012

Hôpital Saint Antoine, Paris

75014

Institut Mutualiste Montsouris, Paris

92118

Hôpital Beaujon, Clichy

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

NCT01718327 - A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma | Biotech Hunter | Biotech Hunter